A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives

Int J Cardiol. 2017 Jan 15;227:127-133. doi: 10.1016/j.ijcard.2016.11.033. Epub 2016 Nov 9.


The DESolve® scaffold (Elixir Medical Corporation, Sunnyvale, California, USA) is manufactured from a poly-l-lactide based polymer and elutes an anti-proliferative, anti-inflammatory drug, Novolimus from a poly-l-lactide based topcoat mixture. The strut thickness is 150μm and the scaffold has platinum-iridium radiopaque markers at both ends. Radial support is available during the early time period to prevent recoil. The scaffold biodegrades within 1year (>90% reduction in molecular weight) and then completely bioresorbs within 2years. The DESolve® scaffold permits a wide range of expansion with a consequently reduced risk for strut fracture. Lumen and scaffold enlargement is observed within 3-6months in both preclinical and clinical studies potentially allowing for the scaffolded region to respond to vasoactive stimuli. The device has a unique property of self-correction observed in bench top studies, which in clinical practice has the potential to eliminate minor malapposition following deployment.

Keywords: Coronary artery disease; Novolimus-eluting bioresorbable vascular scaffold; Percutaneous coronary intervention.

Publication types

  • Review

MeSH terms

  • Absorbable Implants / statistics & numerical data*
  • Coronary Angiography / methods
  • Coronary Stenosis / diagnostic imaging
  • Coronary Stenosis / therapy*
  • Drug-Eluting Stents / standards*
  • Drug-Eluting Stents / trends
  • Female
  • Follow-Up Studies
  • Forecasting
  • Humans
  • Macrolides / pharmacology*
  • Male
  • Percutaneous Coronary Intervention / instrumentation*
  • Percutaneous Coronary Intervention / methods
  • Risk Assessment
  • Tissue Scaffolds
  • Treatment Outcome
  • Vascular Patency / physiology


  • Macrolides
  • novolimus